VEGFA and age-related macular degeneration: In therapeutics, an RNA aptamer targeting vascular endothelial growth factor (VEGF) has been approved by the FDA for age-related macular degeneration treatment, and about a dozen aptamers are in late stage clinical trials [19], [20].